Azure Dominique Grant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Azure Dominique Grant has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Lance J. Kriegsfeld
Department of Neuroscience, University of California, Berkeley
5 shared publications Veronica Luna
People Science, Inc, Los Angeles, CA
5 shared publicationsJordan Moos
People Science, Inc, Los Angeles, CA
4 shared publicationsMarie Crisel B. Erfe
People Science, Inc. Los Angeles California USA
4 shared publicationsArmenouhi Kazaryan
People Science, Inc
3 shared publications- Noah Craft
People Science, Inc
3 shared publications
Latest Publications
- Open Access
- 19 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Effects of a Prebiotic Functional Soda on Gastrointestinal Symptoms in Adults Receiving GLP ‐1–Based Therapy for Weight Management: A Randomized Controlled Pilot Trial
Aims: Gastrointestinal (GI) adverse effects are common during glucagon‐like peptide‐1 (GLP‐1)–based therapy and may negatively affect quality of life (QOL) and treatment persistence. This pilot evaluated the effects of daily consumption of a prebiotic functional soda on GI symptom burden in adults who recently initiated GLP‐1–based therapy for weight management. Materials and Methods: In this open‐label, randomized controlled pilot, 80 adults receiving semaglutide or tirzepatide for weight management and experiencing at least one GI symptom were randomized 1:1 to consume a prebiotic functional soda (OLIPOP; 1 can/day, with the option of 2 cans/day) for 4 weeks or continue their usual free‐living fluid intake. The primary outcome was change in Gastrointestinal Symptom Rating Scale (GSRS) total score. Secondary outcomes included GSRS subscales, health‐related QOL (SF‐36), stool characteristics and frequency, appetite and cravings, dietary intake and GI rescue medication use. Results: Sixty‐eight participants completed the study (intervention, n = 36; control, n = 32). GSRS total score decreased significantly more with the prebiotic functional soda than control (adjusted least‐squares [LS] mean change, −0.931 vs. −0.405; between‐group difference, −0.526 [95% CI: −0.713 to −0.339]; p < 0.001). Greater reductions were observed for constipation, abdominal pain and indigestion relative to control. The group difference in overall SF‐36 scores was also significant ( p = 0.037). Conclusions: Four weeks of daily prebiotic functional soda consumption was associated with greater reductions in participant‐reported GSRS scores compared with usual fluid intake among adults receiving GLP‐1–based therapy for weight management. These preliminary findings warrant confirmation in larger, blinded trials using a matched beverage control. Trial Registration: ClinicalTrials.gov Identifier: NCT07744360
- 19 November 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
Open AccessEffects of a Prebiotic Functional Soda on Gastrointestinal Symptoms in Adults Receiving GLP ‐1–Based Therapy for Weight Management: A Randomized Controlled Pilot Trial
Aims: Gastrointestinal (GI) adverse effects are common during glucagon‐like peptide‐1 (GLP‐1)–based therapy and may negatively affect quality of life (QOL) and treatment persistence. This pilot evaluated the effects of daily consumption of a prebiotic functional soda on GI symptom burden in adults who recently initiated GLP‐1–based therapy for weight management. Materials and Methods: In this open‐label, randomized controlled pilot, 80 adults receiving semaglutide or tirzepatide for weight management and experiencing at least one GI symptom were randomized 1:1 to consume a prebiotic functional soda (OLIPOP; 1 can/day, with the option of 2 cans/day) for 4 weeks or continue their usual free‐living fluid intake. The primary outcome was change in Gastrointestinal Symptom Rating Scale (GSRS) total score. Secondary outcomes included GSRS subscales, health‐related QOL (SF‐36), stool characteristics and frequency, appetite and cravings, dietary intake and GI rescue medication use. Results: Sixty‐eight participants completed the study (intervention, n = 36; control, n = 32). GSRS total score decreased significantly more with the prebiotic functional soda than control (adjusted least‐squares [LS] mean change, −0.931 vs. −0.405; between‐group difference, −0.526 [95% CI: −0.713 to −0.339]; p < 0.001). Greater reductions were observed for constipation, abdominal pain and indigestion relative to control. The group difference in overall SF‐36 scores was also significant ( p = 0.037). Conclusions: Four weeks of daily prebiotic functional soda consumption was associated with greater reductions in participant‐reported GSRS scores compared with usual fluid intake among adults receiving GLP‐1–based therapy for weight management. These preliminary findings warrant confirmation in larger, blinded trials using a matched beverage control. Trial Registration: ClinicalTrials.gov Identifier: NCT07744360
- Open Access
Immune Defense Protein IDP® Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Upper respiratory infections are common and carry a greater burden in older adults. IDP ® (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP ® report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP ® supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods: This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP® /day, and advanced dose of 200mg IDP® /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results: N=255 participants (n=88 Placebo, n=85 50 mg IDP®, n=82 200 mg IDP®) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP® and 200 mg IDP® groups compared to Placebo (KW for Area Under the Curve p 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions: Sixteen weeks of daily IDP® supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP® appears safe and tolerable. Trial Registration: The trial was reviewed and approved by BeyondBound IRB: BB2511NC-152, and registered at clinicaltrials.gov ( NCT07431840 )
Open AccessImmune Defense Protein IDP® Improves Cough and Chest Congestion During Cold and Flu Season in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Upper respiratory infections are common and carry a greater burden in older adults. IDP ® (Immune Defense Protein) is a dietary supplement whose active ingredient is a complex of milk-derived bioactive whey proteins. Prior studies of IDP ® report enhanced antibody response following influenza vaccination, suggesting a potential for reduction of incidence, duration, and severity of upper respiratory symptoms. This study evaluated the effects of IDP ® supplementation on the incidence, type, duration, and severity of upper respiratory symptoms in older adults during cold and flu season, along with rescue medication use and quality of life. Methods: This was a randomized, double-blind, placebo-controlled study with three arms (placebo, standard dose of 50mg IDP® /day, and advanced dose of 200mg IDP® /day). Participants completed a one-week baseline period followed by a 16-week product use period, reporting daily upper respiratory symptoms via the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Participants additionally logged quality of life using the Short Form 36 (SF-36). ANCOVA for change from baseline, mixed models for repeated measures (MRMM), as well as Kruskal Wallis (KW) tests of area under the curve of symptom frequency and severity were used to compare trajectories over time. Results: N=255 participants (n=88 Placebo, n=85 50 mg IDP®, n=82 200 mg IDP®) were evaluated. Analysis of individual symptom trends over time revealed that chest congestion and cough decreased in severity and duration significantly faster in the 50 mg IDP® and 200 mg IDP® groups compared to Placebo (KW for Area Under the Curve p 0.05). SF-36 quality of life did not differ between arms. Adverse events potentially attributable to product use were infrequent, resolved, and did not differ between arms. Conclusions: Sixteen weeks of daily IDP® supplementation was associated with a reduction in duration and severity of cough and chest congestion in older adults. IDP® appears safe and tolerable. Trial Registration: The trial was reviewed and approved by BeyondBound IRB: BB2511NC-152, and registered at clinicaltrials.gov ( NCT07431840 )
- Open Access
CLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
Open AccessCLB101 TM Improves Gastrointestinal Symptom Burden in Overweight Adults: A Randomized, Double-Blind, Placebo-Controlled Study
Background: Anaerostipes caccae CLB101 TM is a next-generation probiotic that directly produces butyrate and is hypothesized to reduce gastrointestinal symptoms by strengthening intestinal barrier integrity. Clinical evidence for A. caccae in symptomatic adult populations remains limited. Methods: Ninety-three adults were randomized 1:1 to CLB101 TM (n=47) or placebo (n=46) for 28 days. The primary outcome was safety and tolerability as assessed by the number, frequency, and severity of adverse events. Secondary outcomes were focused on exploring signals of efficacy, and included change in the Gastrointestinal Symptom Rating Scale (GSRS) composite score from baseline to Week 4. Five GSRS subcategories were additionally evaluated. Exploratory endpoints included daily self-reported GI symptoms, as well as stool and blood measures of intestinal barrier function. Results: 71 participants were evaluated for the GSRS (77.5% female, aged 42.1 SD 12 years, BMI mean 31.3 SD 3.6). No adverse events were reported in the placebo arm, while three self-limiting adverse events were associated with CLB101 TM administration. CLB101 TM reduced GI symptom burden versus placebo on the primary GSRS composite at Week 4 (mean change: −1.60 vs −0.90; MWU p=0.040). Two secondary subscales reached significance after FDR-BH correction: Reflux (mean change: −1.26 vs −0.30; FDR-adjusted p=0.024) and Abdominal Pain (mean change: −1.86 vs −0.83; FDR-adjusted p=0.024). Daily symptom diaries showed trends toward greater reductions in abdominal discomfort, bloating, and flatulence in the active arm at the end of study. This study population did not demonstrate signs of intestinal barrier dysfunction. Product adherence averaged 97.7%. Conclusions: CLB101 TM was safe and tolerable and significantly improved overall GI symptom burden, reflux, and abdominal pain after four weeks of daily supplementation in overweight symptomatic adults. Trial Registration: The trial was approved by Sterling IRB (14583-NACraft) and registered with ClinicalTrials.gov ( NCT07336615 ).
- Open Access
A randomized, double□blind, placebo□controlled study evaluating the impact of Hericium erinaceus (Lion’s Mane) on cognitive performance and subjective wellbeing
Hericium erinaceus (Lion’s Mane) is a functional mushroom with a long history of culinary and traditional use, as well as potential neurotrophic and mood□modulating properties. Evidence for its effects on cognitive performance under real□world conditions, however, remains limited. In this randomized, double□blind, placebo□controlled trial, adults aged 40–75 years with self□reported cognitive difficulty completed a one□week baseline followed by eight weeks of daily supplementation with 2 g of H. erinaceus fruiting body and mycelial biomass or placebo. Cognitive performance using a computerized battery, as well as daily subjective assessments of sleep and wellbeing, were collected remotely. 109 Participants were included in the primary analysis ( H. erinaceus , n = 57; placebo, n = 52). H. erinaceus was associated with significantly greater improvement in visual attention and working memory (Juggle Factor task), subjective sleep quality, morning restedness, and mood compared with placebo ( p < 0.05). No adverse events were reported in participants receiving H. erinaceus . Together, H. erinaceus supplementation modestly improved visual attention and was associated with faster improvements in sleep quality, restedness, and mood in adults with subjective cognitive concerns.
Open AccessA randomized, double□blind, placebo□controlled study evaluating the impact of Hericium erinaceus (Lion’s Mane) on cognitive performance and subjective wellbeing
Hericium erinaceus (Lion’s Mane) is a functional mushroom with a long history of culinary and traditional use, as well as potential neurotrophic and mood□modulating properties. Evidence for its effects on cognitive performance under real□world conditions, however, remains limited. In this randomized, double□blind, placebo□controlled trial, adults aged 40–75 years with self□reported cognitive difficulty completed a one□week baseline followed by eight weeks of daily supplementation with 2 g of H. erinaceus fruiting body and mycelial biomass or placebo. Cognitive performance using a computerized battery, as well as daily subjective assessments of sleep and wellbeing, were collected remotely. 109 Participants were included in the primary analysis ( H. erinaceus , n = 57; placebo, n = 52). H. erinaceus was associated with significantly greater improvement in visual attention and working memory (Juggle Factor task), subjective sleep quality, morning restedness, and mood compared with placebo ( p < 0.05). No adverse events were reported in participants receiving H. erinaceus . Together, H. erinaceus supplementation modestly improved visual attention and was associated with faster improvements in sleep quality, restedness, and mood in adults with subjective cognitive concerns.
- Open Access
A Novel Fasting Mimetic (Mimio™) Improves Hunger, Digestion, Oxidative Stress, and Cardiometabolic Markers in Overweight Adults with Elevated HbA1c: a Double-Blind, Randomized, Placebo-Controlled Trial
This decentralized, double-blind, randomized, placebo-controlled trial investigated the impact of a novel fasting mimetic “Mimio ™ ” on hunger, satiety, digestive symptoms, metabolism, cognition and wellbeing in overweight older adults with elevated HbA1c. Participants collected 2 weeks of baseline subjective data along with a fasted metabolic blood panel. The Mimio fasting mimetic, containing spermidine, nicotinamide, palmitoylethanolamide (PEA) and oleoethanolamide (OEA), or a placebo capsule was then taken before the first meal of the day for 8 weeks. Subjective measures were repeatedly collected throughout the study and metabolic bloodwork was repeated at the end of 8 weeks. 42 Participants were evaluated (47.6% female, BMI 27.6 (0.2) kg/m 2 , aged 62 ± 4, HbA1c 6.0 ± 0.1, n=23 intervention and n=19 placebo). Mimio improved more over time in all hunger and satiety metrics than placebo (Hunger and Satiety Composite Score Mann-Kendall p=2.2*10 -16 ). More participants in the Mimio group improved daily ratings of hunger and appetite compared to placebo, including 91% vs. 47% of participants improving mealtime appetite across the study (Fisher’s Exact Test p=0.003). The Mimio cohort reported significantly less abdominal pain and bloating than the placebo group (Mann-Whitney U p™ , a daily fasting mimetic supplement, improves daily hunger and satiety, reduces oxidative stress, symptoms of indigestion and improves cardiometabolic health markers in overweight older adults with elevated HbA1c. This is the first study to show that fasting mimetic supplementation can recreate clinical fasting-like cardiometabolic benefits without lifestyle changes or the need to fast. Trial Registration: The trial was IRB approved and registered with ClinicalTrials.gov (Pro00080269).
Open AccessA Novel Fasting Mimetic (Mimio™) Improves Hunger, Digestion, Oxidative Stress, and Cardiometabolic Markers in Overweight Adults with Elevated HbA1c: a Double-Blind, Randomized, Placebo-Controlled Trial
This decentralized, double-blind, randomized, placebo-controlled trial investigated the impact of a novel fasting mimetic “Mimio ™ ” on hunger, satiety, digestive symptoms, metabolism, cognition and wellbeing in overweight older adults with elevated HbA1c. Participants collected 2 weeks of baseline subjective data along with a fasted metabolic blood panel. The Mimio fasting mimetic, containing spermidine, nicotinamide, palmitoylethanolamide (PEA) and oleoethanolamide (OEA), or a placebo capsule was then taken before the first meal of the day for 8 weeks. Subjective measures were repeatedly collected throughout the study and metabolic bloodwork was repeated at the end of 8 weeks. 42 Participants were evaluated (47.6% female, BMI 27.6 (0.2) kg/m 2 , aged 62 ± 4, HbA1c 6.0 ± 0.1, n=23 intervention and n=19 placebo). Mimio improved more over time in all hunger and satiety metrics than placebo (Hunger and Satiety Composite Score Mann-Kendall p=2.2*10 -16 ). More participants in the Mimio group improved daily ratings of hunger and appetite compared to placebo, including 91% vs. 47% of participants improving mealtime appetite across the study (Fisher’s Exact Test p=0.003). The Mimio cohort reported significantly less abdominal pain and bloating than the placebo group (Mann-Whitney U p™ , a daily fasting mimetic supplement, improves daily hunger and satiety, reduces oxidative stress, symptoms of indigestion and improves cardiometabolic health markers in overweight older adults with elevated HbA1c. This is the first study to show that fasting mimetic supplementation can recreate clinical fasting-like cardiometabolic benefits without lifestyle changes or the need to fast. Trial Registration: The trial was IRB approved and registered with ClinicalTrials.gov (Pro00080269).
- Open Access
- 24 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-12
Lactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study
The major inhibitory neurotransmitter gamma-aminobutyric acid or GABA plays a pivotal role in mood and sleep. GABA exerts sedative and anxiolytic effects both within the central nervous system and through the gut-brain axis, which has generated interest in the potential for gut GABA to modulate mood and sleep. Several bacterial strains can produce GABA, yet their real-world impacts are poorly understood. We investigated the impact of 2 doses of the strain Lactiplantibacillus plantarum Lp815 on anxiety, sleep, mood, quality of life, cognition, heart rate variability and adverse events in adults with mild to moderate anxiety over a 6-week period. The trial was structured as a double-blinded, randomised, placebo-controlled trial with optional open label extension. Participants were blindly assigned to receive either a placebo, 1 billion colony-forming units (CFU), or 5 billion CFU of the oral capsule per day. Participants completed biweekly anxiety, insomnia and cognition measures, daily mood, sleep, and quality of life surveys, and collected wearable heart rate variability. 83 individuals were evaluated, aged 39 ± 13 years, 63% female and 64% Caucasian. Participants receiving 5 billion CFU exhibited significantly lower anxiety (GAD-7) scores at weeks 4 and 6 compared to placebo (Kruskal-Wallis ). This result was clinically meaningful, with 68% of participants in the 5 billion CFU cohort exhibiting improvement by more than one category in their GAD-7 scores at week 6, compared to 37% in the 1 billion CFU group and 26% in the placebo group (e.g. from moderate to no anxiety) (Fisher’s exact test for 5 billion CFU vs Placebo). No serious adverse events occurred. A daily capsule containing 5 billion CFU Lp815 significantly reduced anxiety in a diverse cohort of adults at 4 and 6 weeks following daily consumption. GABA-producing probiotics may offer a safe option for anxiety reduction in people with mild to moderate anxiety. Trial Registration. The trial was IRB approved and registered with ClinicalTrials.gov (NCT06466603).
- 24 April 2025
- Published by Walter de Gruyter GmbH in Beneficial Microbes
- Vol. -1 (aop) , 1-12
Open AccessLactiplantibacillus plantarum Lp815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study
The major inhibitory neurotransmitter gamma-aminobutyric acid or GABA plays a pivotal role in mood and sleep. GABA exerts sedative and anxiolytic effects both within the central nervous system and through the gut-brain axis, which has generated interest in the potential for gut GABA to modulate mood and sleep. Several bacterial strains can produce GABA, yet their real-world impacts are poorly understood. We investigated the impact of 2 doses of the strain Lactiplantibacillus plantarum Lp815 on anxiety, sleep, mood, quality of life, cognition, heart rate variability and adverse events in adults with mild to moderate anxiety over a 6-week period. The trial was structured as a double-blinded, randomised, placebo-controlled trial with optional open label extension. Participants were blindly assigned to receive either a placebo, 1 billion colony-forming units (CFU), or 5 billion CFU of the oral capsule per day. Participants completed biweekly anxiety, insomnia and cognition measures, daily mood, sleep, and quality of life surveys, and collected wearable heart rate variability. 83 individuals were evaluated, aged 39 ± 13 years, 63% female and 64% Caucasian. Participants receiving 5 billion CFU exhibited significantly lower anxiety (GAD-7) scores at weeks 4 and 6 compared to placebo (Kruskal-Wallis ). This result was clinically meaningful, with 68% of participants in the 5 billion CFU cohort exhibiting improvement by more than one category in their GAD-7 scores at week 6, compared to 37% in the 1 billion CFU group and 26% in the placebo group (e.g. from moderate to no anxiety) (Fisher’s exact test for 5 billion CFU vs Placebo). No serious adverse events occurred. A daily capsule containing 5 billion CFU Lp815 significantly reduced anxiety in a diverse cohort of adults at 4 and 6 weeks following daily consumption. GABA-producing probiotics may offer a safe option for anxiety reduction in people with mild to moderate anxiety. Trial Registration. The trial was IRB approved and registered with ClinicalTrials.gov (NCT06466603).
- Open Access
GABA Probiotic Lactiplantibacillus plantarum Lp815 Improves Sleep, Anxiety and Increases Urinary GABA: a Randomized, Double-Blind, Placebo-Controlled Study
Gamma-aminobutyric acid, or GABA, the major inhibitory neurotransmitter, acts both through the central nervous system and via microbial production in the gut. Strains able to augment gut GABA production could be novel targets for modulation of sleep and mood. We previously demonstrated that Lactiplantibacillus plantarum Lp815 improves symptoms of anxiety. The current study investigates the impact of Lp815 on subjective sleep, mood, digestion and objective wearable sleep data over 6 weeks in adults with self-reported sleep disturbance. The trial was decentralized, double-blind, randomized and placebo controlled. Participants were screened for at least moderate symptoms of insomnia and blindly assigned to receive either a placebo capsule or 5 billion CFU of Lp815 per day. 139 Individuals (5 Billion CFU n=70, placebo n=69) were evaluated, aged 44 ± 13 years, 51.1% female and 55.4% Caucasian. A sub cohort (n=17, 5 Billion CFU n=9, Placebo n=8) submitted a urinary time series for neurotransmitter analysis. Participants who received 5 billion CFU exhibited significantly lower insomnia severity index scores at 6 weeks compared to placebo (p2 =-0.30 and −0.48, respectively). All adverse events potentially related to product use were mild. A daily probiotic containing 5 billion CFU Lp815 significantly improved subjective symptoms of insomnia and anxiety, as well as objective measures of sleep after 6 weeks. Elevation of systemic GABA may contribute to these effects. Short Gamma-aminobutyric acid, or GABA, the major inhibitory neurotransmitter, acts via the central nervous system and microbial production in the gut. Strains that augment gut GABA are novel targets for improving sleep and mood. We previously demonstrated that Lactiplantibacillus plantarum Lp815 improves anxiety symptoms. The current study investigates Lp815’s impact on subjective sleep, mood, digestion and objective wearable sleep data over 6 weeks in adults with self-reported sleep disturbance. The trial was decentralized, double-blind, randomized and placebo-controlled. 139 Individuals (5 Billion CFU/day n=70, placebo n=69) were evaluated, aged 44 ± 13 years, 51.1% female and 55.4% Caucasian. A sub cohort (n=17, 5 Billion CFU n=9, Placebo n=8) collected urine samples for neurotransmitter analysis. Lp815 significantly increased sleep duration metrics, reduced night sweats, lowered insomnia severity index and lowered anxiety scores at 6 weeks compared to placebo (p<0.05), with greater anxiety reduction among women (p<0.01). Finally, urinary GABA increased during week 1 in the Lp815 cohort (p<0.05) and was inversely correlated with insomnia and anxiety. A daily probiotic containing 5 billion CFU Lp815 elevates systemic GABA and improves anxiety, subjective and objective measures of sleep after 6 weeks.
Open AccessGABA Probiotic Lactiplantibacillus plantarum Lp815 Improves Sleep, Anxiety and Increases Urinary GABA: a Randomized, Double-Blind, Placebo-Controlled Study
Gamma-aminobutyric acid, or GABA, the major inhibitory neurotransmitter, acts both through the central nervous system and via microbial production in the gut. Strains able to augment gut GABA production could be novel targets for modulation of sleep and mood. We previously demonstrated that Lactiplantibacillus plantarum Lp815 improves symptoms of anxiety. The current study investigates the impact of Lp815 on subjective sleep, mood, digestion and objective wearable sleep data over 6 weeks in adults with self-reported sleep disturbance. The trial was decentralized, double-blind, randomized and placebo controlled. Participants were screened for at least moderate symptoms of insomnia and blindly assigned to receive either a placebo capsule or 5 billion CFU of Lp815 per day. 139 Individuals (5 Billion CFU n=70, placebo n=69) were evaluated, aged 44 ± 13 years, 51.1% female and 55.4% Caucasian. A sub cohort (n=17, 5 Billion CFU n=9, Placebo n=8) submitted a urinary time series for neurotransmitter analysis. Participants who received 5 billion CFU exhibited significantly lower insomnia severity index scores at 6 weeks compared to placebo (p2 =-0.30 and −0.48, respectively). All adverse events potentially related to product use were mild. A daily probiotic containing 5 billion CFU Lp815 significantly improved subjective symptoms of insomnia and anxiety, as well as objective measures of sleep after 6 weeks. Elevation of systemic GABA may contribute to these effects. Short Gamma-aminobutyric acid, or GABA, the major inhibitory neurotransmitter, acts via the central nervous system and microbial production in the gut. Strains that augment gut GABA are novel targets for improving sleep and mood. We previously demonstrated that Lactiplantibacillus plantarum Lp815 improves anxiety symptoms. The current study investigates Lp815’s impact on subjective sleep, mood, digestion and objective wearable sleep data over 6 weeks in adults with self-reported sleep disturbance. The trial was decentralized, double-blind, randomized and placebo-controlled. 139 Individuals (5 Billion CFU/day n=70, placebo n=69) were evaluated, aged 44 ± 13 years, 51.1% female and 55.4% Caucasian. A sub cohort (n=17, 5 Billion CFU n=9, Placebo n=8) collected urine samples for neurotransmitter analysis. Lp815 significantly increased sleep duration metrics, reduced night sweats, lowered insomnia severity index and lowered anxiety scores at 6 weeks compared to placebo (p<0.05), with greater anxiety reduction among women (p<0.01). Finally, urinary GABA increased during week 1 in the Lp815 cohort (p<0.05) and was inversely correlated with insomnia and anxiety. A daily probiotic containing 5 billion CFU Lp815 elevates systemic GABA and improves anxiety, subjective and objective measures of sleep after 6 weeks.
- Open Access
Combined Effects of Prunus Cerasus (Montmorency Tart Cherry) and Apocynum Venetum (Venetron ® ) On Sleep and Anxiety in Adults with Insomnia
Purpose: Sleep aids derived from traditional plant medicines are strong candidates for safely improving insomnia but require wider validation in patient populations. Methods: We conducted an open label trial of the impact of a compound, Sip2Sleep ® , containing Montmorency tart cherry ( prunus cerasus ) extract and Venetron ® ( apocynum venetum ) on subjective sleep quality, subjective daytime alertness, sleep duration, sleep latency, anxiety, and insomnia in 43 adults with moderate to severe insomnia. Participants collected data over four weeks, with the sleep aid consumed prior to bed during weeks two and four. Results: The Montmorency tart cherry and Venetron ® mixture statistically improved subjective sleep quality, daytime alertness, insomnia symptoms, and anxiety without impacting sleep duration and latency. Subjective improvements in sleep quality exhibited a statistical upward trend across the entire study window, suggesting potential persistence of the compounds days after consumption and greater improvement with longer-term consumption. Conclusions: The combination of Montmorency tart cherry and Venetron ® in this commercially available tincture is a promising sleep aid warranting further investigation in larger trials.
Open AccessCombined Effects of Prunus Cerasus (Montmorency Tart Cherry) and Apocynum Venetum (Venetron ® ) On Sleep and Anxiety in Adults with Insomnia
Purpose: Sleep aids derived from traditional plant medicines are strong candidates for safely improving insomnia but require wider validation in patient populations. Methods: We conducted an open label trial of the impact of a compound, Sip2Sleep ® , containing Montmorency tart cherry ( prunus cerasus ) extract and Venetron ® ( apocynum venetum ) on subjective sleep quality, subjective daytime alertness, sleep duration, sleep latency, anxiety, and insomnia in 43 adults with moderate to severe insomnia. Participants collected data over four weeks, with the sleep aid consumed prior to bed during weeks two and four. Results: The Montmorency tart cherry and Venetron ® mixture statistically improved subjective sleep quality, daytime alertness, insomnia symptoms, and anxiety without impacting sleep duration and latency. Subjective improvements in sleep quality exhibited a statistical upward trend across the entire study window, suggesting potential persistence of the compounds days after consumption and greater improvement with longer-term consumption. Conclusions: The combination of Montmorency tart cherry and Venetron ® in this commercially available tincture is a promising sleep aid warranting further investigation in larger trials.
- Open Access
Deep Learning Model Using Continuous Skin Temperature Data Predicts Labor Onset
Background Changes in body temperature anticipate labor onset in numerous mammals, yet this concept has not been explored in humans. Methods We evaluated patterns in continuous skin temperature data in 91 pregnant women using a wearable smart ring. Additionally, we collected daily steroid hormone samples leading up to labor in a subset of 28 pregnancies and analyzed relationships among hormones and body temperature trajectory. Finally, we developed a novel autoencoder long-short-term-memory (AE-LSTM) deep learning model to provide a daily estimation of days until labor onset. Results Features of temperature change leading up to labor were associated with urinary hormones and labor type. Spontaneous labors exhibited greater estriol to α-pregnanediol ratio, as well as lower body temperature and more stable circadian rhythms compared to pregnancies that did not undergo spontaneous labor. Skin temperature data from 54 pregnancies that underwent spontaneous labor between 34 and 42 weeks of gestation were included in training the AE-LSTM model, and an additional 40 pregnancies that underwent artificial induction of labor or Cesarean without labor were used for further testing. The model was trained only on aggregate 5-minute skin temperature data starting at a gestational age of 240 until labor onset. During cross-validation AE-LSTM average error (true – predicted) dropped below 2 days at 8 days before labor, independent of gestational age. Labor onset windows were calculated from the AE-LSTM output using a probabilistic distribution of model error. For these windows AE-LSTM correctly predicted labor start for 79% of the spontaneous labors within a 4.6-day window at 7 days before true labor, and 7.4-day window at 10 days before true labor. Conclusion Continuous skin temperature reflects progression toward labor and hormonal status during pregnancy. Deep learning using continuous temperature may provide clinically valuable tools for pregnancy care.
Open AccessDeep Learning Model Using Continuous Skin Temperature Data Predicts Labor Onset
Background Changes in body temperature anticipate labor onset in numerous mammals, yet this concept has not been explored in humans. Methods We evaluated patterns in continuous skin temperature data in 91 pregnant women using a wearable smart ring. Additionally, we collected daily steroid hormone samples leading up to labor in a subset of 28 pregnancies and analyzed relationships among hormones and body temperature trajectory. Finally, we developed a novel autoencoder long-short-term-memory (AE-LSTM) deep learning model to provide a daily estimation of days until labor onset. Results Features of temperature change leading up to labor were associated with urinary hormones and labor type. Spontaneous labors exhibited greater estriol to α-pregnanediol ratio, as well as lower body temperature and more stable circadian rhythms compared to pregnancies that did not undergo spontaneous labor. Skin temperature data from 54 pregnancies that underwent spontaneous labor between 34 and 42 weeks of gestation were included in training the AE-LSTM model, and an additional 40 pregnancies that underwent artificial induction of labor or Cesarean without labor were used for further testing. The model was trained only on aggregate 5-minute skin temperature data starting at a gestational age of 240 until labor onset. During cross-validation AE-LSTM average error (true – predicted) dropped below 2 days at 8 days before labor, independent of gestational age. Labor onset windows were calculated from the AE-LSTM output using a probabilistic distribution of model error. For these windows AE-LSTM correctly predicted labor start for 79% of the spontaneous labors within a 4.6-day window at 7 days before true labor, and 7.4-day window at 10 days before true labor. Conclusion Continuous skin temperature reflects progression toward labor and hormonal status during pregnancy. Deep learning using continuous temperature may provide clinically valuable tools for pregnancy care.
- Open Access
Clustering of >145,000 Symptom Logs Reveals Distinct Pre, Peri, and Post Menopausal Phenotypes
Background and Objectives: The transition to menopause is commonly associated with disappearance of menstrual cycle symptoms and emergence of vasomotor symptoms. Although menopausal women report a variety of mood, digestive, and pain symptoms, it remains unclear what symptoms emerge prior to menopause, if symptoms occur in predictable clusters, how these clusters change from across the premenopause-perimenopause-menopause transition, or if distinct phenotypes are present within each life stage. Methods: We present analysis of self-reported symptom presentation in premenopausal to menopausal women using the MenoLife app, which includes 4,789 (n=1,115(23%) premenopausal, n=1,388(29%) perimenopausal, n=2,286(48%) menopausal) individuals and 147,501 (n=27,371(19%) premenopausal, n=57,964(39%) perimenopausal, n=61,806(42%) menopausal) symptom logs. Clusters generated from logs of 45 different symptoms were assessed for similarities across methods: hierarchical clustering analysis (HCA), K-Means clustering of principal components of symptom reporting, and binomial network analysis. Participants were further evaluated based on menstrual cycle regularity or type of menopause. Results: Menstrual cycle-associated symptoms (e.g., cramps, breast swelling), digestive, mood, and integumentary symptoms were characteristic of premenopausal women. Vasomotor symptoms, pain, mood, and cognitive symptoms were characteristic of menopause. Perimenopausal women exhibited both menstrual cycle-associated and vasomotor symptoms. Subpopulations across life stages presented with additional correlated mood and cognitive symptoms, integumentary complaints, digestive, nervous, or sexual symptoms. Symptoms also differed among women depending on the reported regularity of their menstrual cycles or the way in which they entered menopause. Notably, we identified a set of symptoms that were very common across life stages: fatigue, headache, anxiety, and brain fog. We consistently identified the lack of predictive power of hot flashes for other symptoms except night sweats. Conclusions: Together, premenopausal women exhibit menstrual cycle-associated symptoms and menopausal women reported vasomotor symptoms, perimenopausal women report both; and all report high rates of fatigue, headache, anxiety, and brain fog. Limiting focus of menopausal treatment to vasomotor symptoms, or to premenstrual syndrome in premenopausal women, neglects a large proportion of overall symptom burden. Future research and interventions targeting mood and cognitive, digestive, and integumentary symptoms are needed across stages of female reproductive life.
Open AccessClustering of >145,000 Symptom Logs Reveals Distinct Pre, Peri, and Post Menopausal Phenotypes
Background and Objectives: The transition to menopause is commonly associated with disappearance of menstrual cycle symptoms and emergence of vasomotor symptoms. Although menopausal women report a variety of mood, digestive, and pain symptoms, it remains unclear what symptoms emerge prior to menopause, if symptoms occur in predictable clusters, how these clusters change from across the premenopause-perimenopause-menopause transition, or if distinct phenotypes are present within each life stage. Methods: We present analysis of self-reported symptom presentation in premenopausal to menopausal women using the MenoLife app, which includes 4,789 (n=1,115(23%) premenopausal, n=1,388(29%) perimenopausal, n=2,286(48%) menopausal) individuals and 147,501 (n=27,371(19%) premenopausal, n=57,964(39%) perimenopausal, n=61,806(42%) menopausal) symptom logs. Clusters generated from logs of 45 different symptoms were assessed for similarities across methods: hierarchical clustering analysis (HCA), K-Means clustering of principal components of symptom reporting, and binomial network analysis. Participants were further evaluated based on menstrual cycle regularity or type of menopause. Results: Menstrual cycle-associated symptoms (e.g., cramps, breast swelling), digestive, mood, and integumentary symptoms were characteristic of premenopausal women. Vasomotor symptoms, pain, mood, and cognitive symptoms were characteristic of menopause. Perimenopausal women exhibited both menstrual cycle-associated and vasomotor symptoms. Subpopulations across life stages presented with additional correlated mood and cognitive symptoms, integumentary complaints, digestive, nervous, or sexual symptoms. Symptoms also differed among women depending on the reported regularity of their menstrual cycles or the way in which they entered menopause. Notably, we identified a set of symptoms that were very common across life stages: fatigue, headache, anxiety, and brain fog. We consistently identified the lack of predictive power of hot flashes for other symptoms except night sweats. Conclusions: Together, premenopausal women exhibit menstrual cycle-associated symptoms and menopausal women reported vasomotor symptoms, perimenopausal women report both; and all report high rates of fatigue, headache, anxiety, and brain fog. Limiting focus of menopausal treatment to vasomotor symptoms, or to premenstrual syndrome in premenopausal women, neglects a large proportion of overall symptom burden. Future research and interventions targeting mood and cognitive, digestive, and integumentary symptoms are needed across stages of female reproductive life.